Cargando…

Romosozumab and cardiovascular safety in Japan

Romosozumab is a potent pharmacological tool to prevent fractures in osteoporosis patients, and its mechanism of action is distinct from any other drugs. The efficacy of romosozumab to prevent osteoporotic fractures is remarkable. However, there remains a concern of increased cardiovascular adverse...

Descripción completa

Detalles Bibliográficos
Autor principal: Takeuchi, Yasuhiro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Korean Society of Osteoporosis 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8486612/
https://www.ncbi.nlm.nih.gov/pubmed/34632110
http://dx.doi.org/10.1016/j.afos.2021.09.002
_version_ 1784577779460734976
author Takeuchi, Yasuhiro
author_facet Takeuchi, Yasuhiro
author_sort Takeuchi, Yasuhiro
collection PubMed
description Romosozumab is a potent pharmacological tool to prevent fractures in osteoporosis patients, and its mechanism of action is distinct from any other drugs. The efficacy of romosozumab to prevent osteoporotic fractures is remarkable. However, there remains a concern of increased cardiovascular adverse events. Further relevant investigations are essential to understand whether romosozumab is actually involved in the development of cardiovascular events or not. We need more robust evidence to establish an appropriate and reasonable guide to prescribe romosozumab in our clinical practice.
format Online
Article
Text
id pubmed-8486612
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Korean Society of Osteoporosis
record_format MEDLINE/PubMed
spelling pubmed-84866122021-10-07 Romosozumab and cardiovascular safety in Japan Takeuchi, Yasuhiro Osteoporos Sarcopenia Review Article Romosozumab is a potent pharmacological tool to prevent fractures in osteoporosis patients, and its mechanism of action is distinct from any other drugs. The efficacy of romosozumab to prevent osteoporotic fractures is remarkable. However, there remains a concern of increased cardiovascular adverse events. Further relevant investigations are essential to understand whether romosozumab is actually involved in the development of cardiovascular events or not. We need more robust evidence to establish an appropriate and reasonable guide to prescribe romosozumab in our clinical practice. Korean Society of Osteoporosis 2021-09 2021-09-09 /pmc/articles/PMC8486612/ /pubmed/34632110 http://dx.doi.org/10.1016/j.afos.2021.09.002 Text en © 2021 The Korean Society of Osteoporosis. Publishing services by Elsevier B.V. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Review Article
Takeuchi, Yasuhiro
Romosozumab and cardiovascular safety in Japan
title Romosozumab and cardiovascular safety in Japan
title_full Romosozumab and cardiovascular safety in Japan
title_fullStr Romosozumab and cardiovascular safety in Japan
title_full_unstemmed Romosozumab and cardiovascular safety in Japan
title_short Romosozumab and cardiovascular safety in Japan
title_sort romosozumab and cardiovascular safety in japan
topic Review Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8486612/
https://www.ncbi.nlm.nih.gov/pubmed/34632110
http://dx.doi.org/10.1016/j.afos.2021.09.002
work_keys_str_mv AT takeuchiyasuhiro romosozumabandcardiovascularsafetyinjapan